Navigation Links
Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales
Date:11/6/2008

dical Branded sales (24% increase on a constant currency basis) offset by a 16% decrease in Private Label Sales (16% decrease on a constant currency basis).

Non-GAAP Net Income for the current year is $2,776,000 or $.22 per diluted share compared to Non-GAAP net income of $4,966,000 or $.40 per diluted share for the previous year. The decrease for the current year is primarily attributable to the increased strategic investment in Sales and Marketing Programs.

Due to significant swings in the currency exchange rates, the Company is now also showing sales levels on a constant currency basis. In the fourth quarter the dollar strengthened significantly versus the pound sterling, thus affecting Branded sales growth levels in actual dollars.

Commenting on today's announcement, Rochester Medical's CEO and President Anthony J. Conway said, "We had an excellent quarter and excellent year, and we look forward to building on that success in the United States, the United Kingdom, and other global markets. Our planned investments in Sales and Marketing are showing strong results. We are very pleased with the increasing interest in our Infection Control Catheters and with the solid growth in our Intermittent Catheter Sales. As we have previously stated, we look forward to exciting new product introductions this year which will further boost our reputation as a leader in the industry and also help boost our sales. We expect 2009 to be a good year for Rochester Medical."

Rochester Medical has provided Non-GAAP Net Income in addition to earnings calculated in accordance with generally accepted accounting principles (GAAP) because management believes Non-GAAP Net Income provides a more consistent basis for comparisons that are not influenced by certain charges and non-cash expenses and are therefore helpful in understanding Rochester Medical's underlying operating results. Non-GAAP Net Income is not a measure of financial performance under GAAP, and should
'/>"/>

SOURCE Rochester Medical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. U.S. Reps. Oberstar and Walz Discuss DM&E Railroad Expansion With Rochester, Minn. Leaders
2. Rochester Medical Reports Record Fourth Quarter Sales and Record Year
3. Rochester Medical Announces First Quarter 2008 Earnings Conference Call February 4, 2008
4. Mayo Clinic Seeks Mitigation for Rochester as Condition of Canadian Pacific - DM&E Railroad Merger
5. Rochester Medical Applauds Improved U.S. Medicare Coverage Policy for Intermittent Catheters
6. Rochester Medical Marketing VP Retires
7. Rochester Coalition and Mayo Clinic Challenge Railroads Contention That Hazmat Rail Shipments Pose no Risk
8. Rochester Medical Honored by Premier Healthcare Alliance for Exceeding Performance Expectations
9. Autovan Donates Wheelchair-Accessible Van; Brings Greater Mobility to Facility in Rochester, New York
10. Rochester Medical Implants Achieves ISO 13485:2003 Certification for Medical Device Manufacturing
11. Safety Threat to Rochester Still Remains Despite Approval Of Canadian Pacifics Railroad Acquisition Of DM&E
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2014)... Pwnie Express today announced the release ... Plug, the R3, an inconspicuous pentesting device whose drop ... remote locations at a fraction of the cost of ... the only company to assess wired and wireless network ... a next-generation penetration testing device in a portable, shippable, ...
(Date:9/3/2014)... 03, 2014 Morris Psychological ... free screenings for depression on October 9, 2014 ... Court). More than 1,000 organizations nationwide will be ... colleges and military installations. After completing a screening, ... and agencies that can offer further evaluation and ...
(Date:9/2/2014)... 03, 2014 Autumn is well ... to celebrate the new season with worldwide people. ... and announced that Hostgator ( http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts ), Arvixe, ... of 2014. , Since 2002 HostGator has ... and the company’s reputation for reliability remains with ...
(Date:9/2/2014)... Fla. (PRWEB) September 02, 2014 ... join together in Tampa Bay from September 4-6 ... annual Scientific Symposium and FARA Energy Ball Gala. ... USF Ataxia Research Center in their pursuit of ... affected by the progressive neuromuscular disease Friedreich’s ataxia ...
(Date:9/2/2014)... 03, 2014 UWDress.com, an experienced supplier ... added a lot of fashionable bridesmaid dresses ... company has launched a special offer to celebrate the ... from 20 to 60 percent off. , The ... announce our new fashionable bridesmaid dresses for consumers from ...
Breaking Medicine News(10 mins):Health News:Pwnie Express Releases Next Generation Penetration Testing Device: The Pwn Plug R3 2Health News:Pwnie Express Releases Next Generation Penetration Testing Device: The Pwn Plug R3 3Health News:Pwnie Express Releases Next Generation Penetration Testing Device: The Pwn Plug R3 4Health News:Screenings for Depression by Morris Psychological Group, October 9, 2014 from 4:30 to 8:30pm, Rockaway Townsquare Mall (Macy’s Court) 2Health News:Top10BestSEOHosting.com Celebrates The Coming Of Autumn And Release Reseller Hosting Suppliers Of 2014 2Health News:Event Gathers World-Renowned Researchers and Community Leaders to Find a Cure for Rare Disease, Friedreich’s Ataxia 2Health News:Event Gathers World-Renowned Researchers and Community Leaders to Find a Cure for Rare Disease, Friedreich’s Ataxia 3Health News:Elegant Bridesmaid Dresses For 2014, Latest Designs From UWDress.com 2
... DENVER, July 28 ThinIdentity Corporation, a ... announced that Alegent Health is moving forward with plans ... The first installation is located at its Mercy Hospital ... has over 1,000 caregivers using the ThinIdentity solution to ...
... , WILMINGTON, Delaware, July 28 ... - 2014), published by,MarketsandMarkets ( http://www.marketsandmarkets.com ), the total drug-device,combination ... out of,which the U.S. market will account for nearly 30.9% ... a CAGR of 11.8% from 2009 to 2014. , ...
... ... CompactRIO embedded real-time platform at the 15th annual NIWeek, opening Aug. 4 at the ... and exhibition hosted by National Instruments. , ... Irvine, CA (PRWEB) July 27, 2009 -- MoviMED ( www.movimed.com ...
... ... find medical assistant training at All Allied Health Schools. , ... Seattle, Wash. (PRWEB) July 28, 2009 -- With current unemployment ... In 2006, the Bureau of Labor Statistics predicted 35 percent growth in medical assistant ...
... ... centers and healthcare facilities acquire financing for new and professionally refurbished medical equipment. , ... (Vocus) July 28, 2009 -- With ... to purchase medical equipment . DRE, Inc. — named a Company of the Year ...
... , ... Cleanroom wipers manufactured by Teknipure offer innovative ... to finish in one facility enabling maximum quality control and are ... Basis Weight, Sorbency, Liquid Particle Count, Non-Volatile Residue levels, Ionic Extractable ...
Cached Medicine News:Health News:Alegent Health Turns to ThinIdentity(TM) to Improve Caregiver Productivity 2Health News:Alegent Health Turns to ThinIdentity(TM) to Improve Caregiver Productivity 3Health News:Drug-Device Combination Market Worth US$18.54 Billion by 2014 2Health News:Drug-Device Combination Market Worth US$18.54 Billion by 2014 3Health News:MoviMED Announces Participation in NIWeek 2009 Conference to Examine Trends and Technologies for Boosting Productivity and Increasing Competitive Advantage 2Health News:MoviMED Announces Participation in NIWeek 2009 Conference to Examine Trends and Technologies for Boosting Productivity and Increasing Competitive Advantage 3Health News:Students Connect with Stable Careers Through Updated Medical Assistant Career Resources on All Allied Health Schools 2Health News:Students Connect with Stable Careers Through Updated Medical Assistant Career Resources on All Allied Health Schools 3Health News:Financing Available for Healthcare Equipment from DRE Medical Equipment 2Health News:Financing Available for Healthcare Equipment from DRE Medical Equipment 3Health News:Teknipure Cleanroom Wipers Offer Innovative Solutions for Contamination Control Engineers 2
(Date:9/2/2014)... 2014 Perrigo Company plc, a public limited company ... (the " Company "), today announced that it is offering ... new 1.30% Senior Notes due 2016 (the " 2016 Exchange ... 2018 (the " 2018 Exchange Notes "), $800,000,000 of its ... Notes ") and $400,00,000 of its new 5.30% Senior Notes ...
(Date:9/2/2014)... AUSTIN, Texas , Sept. 2, 2014 /PRNewswire/ ... Phase III study being conducted in the US ... a True Human™ monoclonal antibody therapy, is being ... is further complicated with cachexia. The primary endpoint ... in Xilonix treated patients to a control population ...
(Date:9/2/2014)... NEW YORK , Sept. 2, 2014 /PRNewswire/ ... report is available in its catalogue: ... 2014 http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html ... H2, 2014 Summary GlobalData,s clinical ... Review, H2, 2014" provides data on the Acute ...
Breaking Medicine Technology:Perrigo Company plc Announces Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023 and 5.30% Senior Notes Due 2043 2Perrigo Company plc Announces Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023 and 5.30% Senior Notes Due 2043 3Perrigo Company plc Announces Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023 and 5.30% Senior Notes Due 2043 4XBiotech Halts Study, Reports Positive Phase III Results with Antibody Therapy for Cancer 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8
... Work Status and,Productivity, WASHINGTON, May 23, 2007 /PRNewswire-FirstCall/ ... (DDW), from,long-term extensions of the ACT trials (Active ... moderately to severely active,ulcerative colitis (UC) who had ... the trials maintained,improvement in their clinical symptoms for ...
... WIRE)--May 23, 2007 - Synta,Pharmaceuticals Corp., (NASDAQ: ... and commercializing small,molecule drugs to treat severe ... data from the Phase 2b clinical,trial in ... drug,candidate, STA-4783, will be presented at the ...
Cached Medicine Technology:Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 2Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 3Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 4Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 5Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 6Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 7Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 8Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 9Synta Oncology Candidate STA-4783 Clinical Trial Results to Be,Presented at the ASCO Annual Meeting 2Synta Oncology Candidate STA-4783 Clinical Trial Results to Be,Presented at the ASCO Annual Meeting 3
... Metrikas pager-sized A1cNow ... technology to provide healthcare ... access to quantitative A1C ... indicator of diabetes management ...
... Vein Treatment. It is estimated that 25% of ... veins. In the United States, more than half ... from painful and unsightly venous disease., The VenaCure ... vascular therapy for the treatment of varicose veins. ...
Inquire...
Inquire...
Medicine Products: